Multicentre, randomised, placebocontrolled trial of extract of Japanese herbal medicine Daikenchuto to prevent bowel dysfunction after adult liver transplantation (DKB 14 Study)

Toshimi Kaido, Tsuyoshi Shimamura, Yasuhiko Sugawara, Hiroshi Sadamori, Ken Shirabe, Michio Yamamoto, Shinji Uemoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: This multicentre randomised controlled clinical trial will aim to determine the ability of an extract (TJ-100) of Daikenchuto (traditional Japanese herbal medicine; Kampo) to prevent bowel dysfunction in at least 110 patients after liver transplantation (LT). Methods and analysis: The following co-primary end points will be evaluated on postoperative day 7: total oral and enteral caloric intake, abdominal distension and abdominal pain. The secondary end points will comprise sequential changes of total oral and enteral caloric intake after LT, sequential changes in numeric rating scales for abdominal distension and pain, elapsed time to the first postoperative passage of stool, quality of life assessment using the Gastrointestinal Symptom Rating Scale score (Japanese version), postoperative liver function, liver regeneration rate, incidence of bacteraemia and bacterial strain, trough level of immunosuppressants, occurrence of acute cellular rejection, discharge or not within 2 months after LT, sequential changes of portal venous flow to the graft and ascites discharge. The two arms of the study will comprise 55 patients per arm. Ethics and dissemination: The study has been conducted according to the CONSORT statement. All participants signed a written consent form, and the study has been approved by the institutional review board of each participating institute and conducted in accordance with the Declaration of Helsinki of 1996. The findings will be disseminated through scientific and professional conferences, and in peer-reviewed journals.

Original languageEnglish
Article numbere008356
JournalBMJ Open
Volume5
Issue number9
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Herbal Medicine
Liver Transplantation
Energy Intake
Abdominal Pain
Small Intestine
Arm
Helsinki Declaration
Kampo Medicine
Consent Forms
Liver Regeneration
Research Ethics Committees
Immunosuppressive Agents
Bacteremia
Ascites
Ethics
Randomized Controlled Trials
Quality of Life
Transplants
Liver
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Multicentre, randomised, placebocontrolled trial of extract of Japanese herbal medicine Daikenchuto to prevent bowel dysfunction after adult liver transplantation (DKB 14 Study). / Kaido, Toshimi; Shimamura, Tsuyoshi; Sugawara, Yasuhiko; Sadamori, Hiroshi; Shirabe, Ken; Yamamoto, Michio; Uemoto, Shinji.

In: BMJ Open, Vol. 5, No. 9, e008356, 2015.

Research output: Contribution to journalArticle

Kaido, Toshimi ; Shimamura, Tsuyoshi ; Sugawara, Yasuhiko ; Sadamori, Hiroshi ; Shirabe, Ken ; Yamamoto, Michio ; Uemoto, Shinji. / Multicentre, randomised, placebocontrolled trial of extract of Japanese herbal medicine Daikenchuto to prevent bowel dysfunction after adult liver transplantation (DKB 14 Study). In: BMJ Open. 2015 ; Vol. 5, No. 9.
@article{f906392e4ea94688bb6b70696a3d68f4,
title = "Multicentre, randomised, placebocontrolled trial of extract of Japanese herbal medicine Daikenchuto to prevent bowel dysfunction after adult liver transplantation (DKB 14 Study)",
abstract = "Introduction: This multicentre randomised controlled clinical trial will aim to determine the ability of an extract (TJ-100) of Daikenchuto (traditional Japanese herbal medicine; Kampo) to prevent bowel dysfunction in at least 110 patients after liver transplantation (LT). Methods and analysis: The following co-primary end points will be evaluated on postoperative day 7: total oral and enteral caloric intake, abdominal distension and abdominal pain. The secondary end points will comprise sequential changes of total oral and enteral caloric intake after LT, sequential changes in numeric rating scales for abdominal distension and pain, elapsed time to the first postoperative passage of stool, quality of life assessment using the Gastrointestinal Symptom Rating Scale score (Japanese version), postoperative liver function, liver regeneration rate, incidence of bacteraemia and bacterial strain, trough level of immunosuppressants, occurrence of acute cellular rejection, discharge or not within 2 months after LT, sequential changes of portal venous flow to the graft and ascites discharge. The two arms of the study will comprise 55 patients per arm. Ethics and dissemination: The study has been conducted according to the CONSORT statement. All participants signed a written consent form, and the study has been approved by the institutional review board of each participating institute and conducted in accordance with the Declaration of Helsinki of 1996. The findings will be disseminated through scientific and professional conferences, and in peer-reviewed journals.",
author = "Toshimi Kaido and Tsuyoshi Shimamura and Yasuhiko Sugawara and Hiroshi Sadamori and Ken Shirabe and Michio Yamamoto and Shinji Uemoto",
year = "2015",
doi = "10.1136/bmjopen-2015-008356",
language = "English",
volume = "5",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Multicentre, randomised, placebocontrolled trial of extract of Japanese herbal medicine Daikenchuto to prevent bowel dysfunction after adult liver transplantation (DKB 14 Study)

AU - Kaido, Toshimi

AU - Shimamura, Tsuyoshi

AU - Sugawara, Yasuhiko

AU - Sadamori, Hiroshi

AU - Shirabe, Ken

AU - Yamamoto, Michio

AU - Uemoto, Shinji

PY - 2015

Y1 - 2015

N2 - Introduction: This multicentre randomised controlled clinical trial will aim to determine the ability of an extract (TJ-100) of Daikenchuto (traditional Japanese herbal medicine; Kampo) to prevent bowel dysfunction in at least 110 patients after liver transplantation (LT). Methods and analysis: The following co-primary end points will be evaluated on postoperative day 7: total oral and enteral caloric intake, abdominal distension and abdominal pain. The secondary end points will comprise sequential changes of total oral and enteral caloric intake after LT, sequential changes in numeric rating scales for abdominal distension and pain, elapsed time to the first postoperative passage of stool, quality of life assessment using the Gastrointestinal Symptom Rating Scale score (Japanese version), postoperative liver function, liver regeneration rate, incidence of bacteraemia and bacterial strain, trough level of immunosuppressants, occurrence of acute cellular rejection, discharge or not within 2 months after LT, sequential changes of portal venous flow to the graft and ascites discharge. The two arms of the study will comprise 55 patients per arm. Ethics and dissemination: The study has been conducted according to the CONSORT statement. All participants signed a written consent form, and the study has been approved by the institutional review board of each participating institute and conducted in accordance with the Declaration of Helsinki of 1996. The findings will be disseminated through scientific and professional conferences, and in peer-reviewed journals.

AB - Introduction: This multicentre randomised controlled clinical trial will aim to determine the ability of an extract (TJ-100) of Daikenchuto (traditional Japanese herbal medicine; Kampo) to prevent bowel dysfunction in at least 110 patients after liver transplantation (LT). Methods and analysis: The following co-primary end points will be evaluated on postoperative day 7: total oral and enteral caloric intake, abdominal distension and abdominal pain. The secondary end points will comprise sequential changes of total oral and enteral caloric intake after LT, sequential changes in numeric rating scales for abdominal distension and pain, elapsed time to the first postoperative passage of stool, quality of life assessment using the Gastrointestinal Symptom Rating Scale score (Japanese version), postoperative liver function, liver regeneration rate, incidence of bacteraemia and bacterial strain, trough level of immunosuppressants, occurrence of acute cellular rejection, discharge or not within 2 months after LT, sequential changes of portal venous flow to the graft and ascites discharge. The two arms of the study will comprise 55 patients per arm. Ethics and dissemination: The study has been conducted according to the CONSORT statement. All participants signed a written consent form, and the study has been approved by the institutional review board of each participating institute and conducted in accordance with the Declaration of Helsinki of 1996. The findings will be disseminated through scientific and professional conferences, and in peer-reviewed journals.

UR - http://www.scopus.com/inward/record.url?scp=84956937455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956937455&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2015-008356

DO - 10.1136/bmjopen-2015-008356

M3 - Article

C2 - 26419681

AN - SCOPUS:84956937455

VL - 5

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 9

M1 - e008356

ER -